"The greatest risk of hubris to human health comes in the form of antibiotic-resistant bacteria."
- The World Economic Forum's Global Risks 2013
Learn how Cubist is leading the battle against superbugs and advancing the R&D of new therapies to treat serious and potentially life threatening infections.
Every day, our experts search for new discoveries and push scientific boundaries in our efforts to deliver powerful medicines for some of the greatest medical challenges. More
12/19/2014 - Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
At Cubist, our culture is our foundation. We share a passion for learning, collaborating, innovating, and most of all, making a difference in people’s lives.